Year: 2007
Type: article
Abstract: On July 30, the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with an increased risk of myocardial ischemic events. Dr. Clifford Rosen reports.
Source: New England Journal of Medicine
DOI: 10.1056/nejmp078167
Author: Clifford J. Rosen
Institution: St. Joseph Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2024874163
